Baader Bank Aktiengesellschaft Purchases New Stake in Theravance Biopharma, Inc. $TBPH

Baader Bank Aktiengesellschaft purchased a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH) during the third quarter, HoldingsChannel.com reports. The fund purchased 53,500 shares of the biopharmaceutical company’s stock, valued at approximately $781,000.

Other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. State of Wyoming raised its position in shares of Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,019 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 1,020 shares during the last quarter. Campbell & CO Investment Adviser LLC boosted its position in Theravance Biopharma by 4.4% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 52,617 shares of the biopharmaceutical company’s stock valued at $768,000 after purchasing an additional 2,225 shares during the period. Finally, Invesco Ltd. grew its stake in Theravance Biopharma by 12.4% during the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 2,789 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at $5,206,781.25. This represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TBPH. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 3rd. Oppenheimer started coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. HC Wainwright lifted their price target on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Stock Up 0.6%

Shares of TBPH stock opened at $19.51 on Thursday. The stock has a 50-day simple moving average of $19.10 and a 200 day simple moving average of $16.14. The stock has a market capitalization of $988.57 million, a P/E ratio of 34.23 and a beta of 0.15. Theravance Biopharma, Inc. has a fifty-two week low of $7.90 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.